News Archives - Congruence

Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025

https://www.prnewswire.com/news-releases/congruence-therapeutics-to-present-preclinical-characterization-of-its-mc4r-corrector-development-candidate-cgx-926-for-genetic-obesity-at-obesityweek-2025-302607289.html

By Araceli Richardson|2025-11-06T07:02:45-08:0011.06.2025|News|0 Comments

Congruence Therapeutics Earns “Fierce 15” Distinction for 2025

https://www.prnewswire.com/news-releases/congruence-therapeutics-earns-fierce-15-distinction-for-2025-302562951.html

By Araceli Richardson|2025-09-22T06:31:52-07:0009.22.2025|News|0 Comments

Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-09-04T08:08:59-07:0009.04.2025|News|0 Comments

Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-07-24T06:04:11-07:0007.24.2025|News|0 Comments

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-07-16T06:02:55-07:0007.16.2025|News|0 Comments

Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-06-03T06:07:21-07:0006.03.2025|News|0 Comments

Congruence Therapeutics Announces Participation at the Citi Biotech Private Access Day and 2025 Bloom Burton & Co. Healthcare Investor Conferences

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-04-28T13:45:12-07:0004.22.2025|News|0 Comments

Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-03-26T13:10:27-07:0003.26.2025|News|0 Comments

Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-12-03T05:02:51-08:0012.03.2024|News|0 Comments

Congruence Therapeutics Announces Blitz Talk Award and Poster Presentations on MC4R-Deficient Genetic Obesity Program at Obesity Week 2024

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-11-03T09:06:59-08:0011.03.2024|News|0 Comments